Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1993 2
1994 1
1995 1
1997 4
1998 1
1999 1
2000 6
2001 5
2002 3
2003 5
2004 4
2005 9
2006 6
2007 5
2008 11
2009 7
2010 9
2011 9
2012 9
2013 10
2014 5
2015 7
2016 6
2018 1
2019 2
2020 2
2021 7
2022 7
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 10475122

127 results

Results by year

Filters applied: . Clear all
Page 1
A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care. Högberg T, et al. Acta Oncol. 2001;40(2-3):340-60. doi: 10.1080/02841860151116420. Acta Oncol. 2001. PMID: 11441940 Review.
Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg ME, Onstenk W, Boere IA, Look M, Ottevanger PB, de Gooyer D, Kerkhofs LG, Valster FA, Ruit JB, van Reisen AG, Goey SH, van der Torren AM, ten Bokkel Huinink D, Kok TC, Verweij J, van Doorn HC. van der Burg ME, et al. Eur J Cancer. 2014 Oct;50(15):2592-601. doi: 10.1016/j.ejca.2014.07.015. Epub 2014 Aug 2. Eur J Cancer. 2014. PMID: 25096168 Clinical Trial.
Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.
García-Sáenz JA, Custodio A, Casado A, Vidart JA, Coronado PJ, Martín M, López-Tarruella S, Puente J, Fernández C, Díaz-Rubio E. García-Sáenz JA, et al. Clin Transl Oncol. 2011 Feb;13(2):121-32. doi: 10.1007/s12094-011-0629-6. Clin Transl Oncol. 2011. PMID: 21324801 Review.
Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.
da Costa Miranda V, de Souza Fêde ÂB, Dos Anjos CH, da Silva JR, Sanchez FB, da Silva Bessa LR, de Paula Carvalho J, Filho EA, de Freitas D, Del Pilar Estevez Diz M. da Costa Miranda V, et al. Gynecol Oncol. 2014 Feb;132(2):287-91. doi: 10.1016/j.ygyno.2013.12.002. Epub 2013 Dec 9. Gynecol Oncol. 2014. PMID: 24333355
Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E, Guastalla JP, Weber B, Curé H, Orfeuvre H, Mousseau M, Vincent P, Diéras V, Tubiana-Mathieu N, Jacquin JP, Mignot L, Leduc B, Paraïso D, Viens P. Pujade-Lauraine E, et al. Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-30-S15-35. Semin Oncol. 1997. PMID: 9346219 Clinical Trial.
127 results